Fulcrum Therapeutics Announces Q3 2024 Financial Results

Fulcrum Therapeutics Reports Q3 2024 Financial Results

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) held its Q3 2024 earnings conference call on November 13, 2024. The call was hosted by key company executives, including Alex Sapir, President and CEO; Alan Musso, CFO; Dr. Pat Horn, Chief Medical Officer; and Dr. Iain Fraser, Senior Vice President of Early Development.

During the call, the company provided updates on its financial performance and discussed progress in its key development programs. The event was webcast live and is available on the Fulcrum Therapeutics website.

Participants in the call included analysts from Oppenheimer, Stifel, Piper Sandler, Cantor Fitzgerald, RBC Capital, Leerink, and Goldman Sachs. The company addressed forward-looking statements concerning future expectations, clinical development timelines, and financial projections, with a reminder that these statements are subject to change.

The call concluded with a Q&A session, where the executive team addressed questions from the participants.